Down Syndrome Biobank Consortium: A perspective

Individuals with Down syndrome (DS) have a partial or complete trisomy of chromosome 21, resulting in an increased risk for early-onset Alzheimer's disease (AD)-type dementia by early midlife. Despite ongoing clinical trials to treat late-onset AD, individuals with DS are often excluded. Furthe...

Descripción completa

Detalles Bibliográficos
Autores: Aldecoa, I, Barroeta, I, Carroll, SL, Fortea, J, Gilmore, A, Ginsberg, SD, Guzman, SJ, Hamlett, ED, Head, E, Perez, SE, Potter, H, Molina-Porcel, L, Raha-Chowdhury, R, Wisniewski, T, Yong, WH, Zaman, S, Ghosh, S, Mufson, EJ, Granholm, AC
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p19255
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19255
http://ddd.uab.cat/record/313086
Access Level:acceso abierto
Palabra clave:Alzheimer's disease
biobanking
brain banking
Down syndrome
repository
research
Descripción
Sumario:Individuals with Down syndrome (DS) have a partial or complete trisomy of chromosome 21, resulting in an increased risk for early-onset Alzheimer's disease (AD)-type dementia by early midlife. Despite ongoing clinical trials to treat late-onset AD, individuals with DS are often excluded. Furthermore, timely diagnosis or management is often not available. Of the genetic causes of AD, people with DS represent the largest cohort. Currently, there is a knowledge gap regarding the underlying neurobiological mechanisms of DS-related AD (DS-AD), partly due to limited access to well-characterized brain tissue and biomaterials for research. To address this challenge, we created an international consortium of brain banks focused on collecting and disseminating brain tissue from persons with DS throughout their lifespan, named the Down Syndrome Biobank Consortium (DSBC) consisting of 11 biobanking sites located in Europe, India, and the USA. This perspective describes the DSBC harmonized protocols and tissue dissemination goals.

Similares en LA Referencia